Moreover, Zhang et al.[123] evaluated the anti-tumor efficacy of the γ-secretase inhibitor PF-03084014 in combination with docetaxel in TNBCs both in vitro and in vivo studies: the authors demonstrated that PF-03084014 improves taxane-based therapy by multiple mechanisms, among them the decrease of MDR1/ABCB1 and ABCC2 transporters[123]. Here, ABCB1 is linked to neoplasm.